CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Go back to CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer| Eaton Vance Dividend Builder Fd Cl C (NASDAQ: CTMX) | Delayed: 3.12 +0.08 (2.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.04 | 52 Week High | $24.68 | |||
| Open | $3.04 | 52 Week Low | $9.10 | |||
| Day High | $3.22 | P/E | N/A | |||
| Day Low | $3.01 | EPS | $0.00 | |||
| Volume | 2,508,315 | |||||
